From the *Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, India; †Homi Bhabha National Institute, Anushaktinagar, Mumbai; ‡Department of Nuclear Medicine and PET, Kovai Medical Center and Hospital, Coimbatore, Tamil Nadu; and §Radiation Medicine Centre, Bhabha Atomic Research Centre, Trombay, Mumbai, India.
Clin Nucl Med. 2017 Mar;42(3):235-236. doi: 10.1097/RLU.0000000000001530.
We have earlier reported the potential of Tm-EDTMP as an alternative cost-effective radiopharmaceutical of SrCl2 for bone pain palliation application. Encouraging results obtained in the radiochemical studies and biological evaluations in animal model have prompted us to initiate the clinical study to evaluate the potential of Tm-EDTMP in human cancer patients. The serial scintigraphic images represent the whole-body scans of a patient (68 years old woman) with skeletal metastases of carcinoma of the breast origin recorded after administering 370 MBq (10 mCi) of Tm-EDTMP at different post-administration time points along with the pre-therapy images recorded with Tc-MDP in the same patient.
我们之前曾报道过 Tm-EDTMP 作为 SrCl2 的替代放射性药物，用于缓解骨痛，具有成本效益。在动物模型中的放射化学研究和生物学评估中获得的令人鼓舞的结果促使我们开始进行临床研究，以评估 Tm-EDTMP 在人类癌症患者中的潜力。连续的闪烁扫描图像代表了一名患有乳腺癌骨转移的患者（68 岁女性）的全身扫描，在给予 370MBq（10mCi）的 Tm-EDTMP 后，在不同的给药后时间点进行记录，同时还记录了同一患者用 Tc-MDP 进行治疗前的图像。
